Transaction · 0001104659-26-113279

Ali Asif

Ali Asif, CFO, reported a transaction classified as exercise at Protagonist Therapeutics, Inc involving 9229.000000 shares for an estimated $359746.42. Reported holdings after the transaction were 68232.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCFO
PTGXProtagonist Therapeutics, Inc
Filing timeOct 02
Trade dateSep 30, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position tradedUnavailableCalculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$140.06
Pre-filing
1mo ago +10.5%1w ago -1.0%1d ago +0.6%
Returns since
7d30d90d180d1y

PTGX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
PTGX since 2026-10-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001104659-26-113279
Common Stock
Transaction date
Sep 30, 2026
Filed Oct 02, 2026, 08:10 PM · 2d delay
Shares
9.22k sh
$38.98 per share
Estimated value
$359k
Computed from shares × price
Holdings after
68.2k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transactions set forth on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2026.

  2. F2

    The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.21 to $143.31. Upon request by the staff of the U.S.…

  3. F3

    The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $140.16 to $143.45. Upon request by the SEC, the Issuer, o…

  4. F4

    The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

  5. F5

    The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

  6. F6

    The stock option is fully vested.

  7. F7

    The stock option vests in 48 equal monthly installments following January 16, 2023, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Original filing · 0001104659-26-113279
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

PTGX